GlassScriptPhysician profile
Sumeet Thareja
NPI 1609165794
$918.18
in general payments reported to CMS, 2019-2025
19 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.88 · 2020: $11.08 · 2021: $221 · 2022: $209 · 2023: $107 · 2024: $165 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $105.45 | 2022-2025 | Ilumya |
| Organogenesis INC. | $91.30 | 2021-2023 | Puraply |
| Biofrontera INC. | $82.30 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $79.62 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $70.40 | 2021-2024 | |
| Strata Skin Sciences, INC. | $65.29 | 2019-2024 | Xtrac |
| Sensus Healthcare, INC. | $33.69 | 2021 | |
| Smith+Nephew, INC. | $32.76 | 2024 | Renasys Go V2 Home |
| Convatec INC. | $29.15 | 2023 | |
| Celgene Corporation | $28.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.06 | 2024 | Farxiga |
| Galderma Laboratories, L.P. | $24.94 | 2019 | |
| Merz North America, INC. | $23.81 | 2021 | |
| Genentech USA, INC. | $22.81 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $21.20 | 2021 | |
| Lilly USA, LLC | $20.42 | 2021 | |
| Novo Nordisk INC | $17.80 | 2025 | Ozempic |
| Genzyme Corporation | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumeet Thareja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.